

**IN THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) A topical gel formulation of oxybutynin consisting essentially of:  
  
0.5-5% (w/w) of oxybutynin chloride salt, 10-80% (w/w) of a short chain alcohol, 0.2-2.0% (w/w) of a gelling agent, 0.5-5.0% of permeation enhancer, 1-3% of a moisturizer, and 1-2% of diisopropanolamine.
2. (Original) The topical gel formulation as in as in Claim 1, wherein the short chain alcohol is ethanol or isopropanol.
3. (Previously presented) The topical gel formulation as in Claim 1, wherein the gelling agent is CARBOMER or PEMULEN TR-1NF.
4. (Previously presented) The topical gel formulation as in Claim 3, wherein the CARBOMER includes CARBOPOL ETD 2020.
5. (Cancelled) The topical gel formulation as in Claim 1, further comprises of 0.5-5.0% (w/w) permeation enhancer.
6. (Previously presented) The topical gel formulation as in Claim 1, wherein the permeation enhancer is selected from the group consisting of propylene glycol, propylene glycol laurate, isopropyl myristate, and methyl lactate.
7. (Cancelled) The topical gel formulation as in Claim 1, wherein the permeation enhancer is isopropyl myristate.
8. (Cancelled) The topical gel formulation as in Claim 1, further comprises of a moisturizer.

9. (Previously presented) The topical gel formulation as in Claim 1, wherein the moisturizer is propylene glycol.
10. (Original) A method for treating bladder disorders in a subject, said method comprising administering to a subject in need thereof an effective amount of a topical gel formulation of oxybutynin according to Claim 1.